Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Orchestra BioMed Holdings, Inc.

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers MDT OBIO
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers MOTS OBIO
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Orchestra BioMed Strengthens Senior Leadership Team
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Tickers OBIO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.